Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Gastro-enteropancreatic neuroendocrine tumor × Magnetic Resonance Spectroscopy × 90 days × Clear all

Sponsor

Conditions

Prostatic Neoplasms 48 Lung Neoplasms 34 Carcinoma, Non-Small-Cell Lung 32 Neoplasm Metastasis 30 Breast Neoplasms 21 Multiple Myeloma 19 Glioblastoma 19 Carcinoma, Renal Cell 19 Brain Neoplasms 19 Melanoma 18 Pancreatic Neoplasms 17 Squamous Cell Carcinoma of Head and Neck 16 Glioma 16 Colorectal Neoplasms 16 Urinary Bladder Neoplasms 15 Mouth Neoplasms 15 Ovarian Neoplasms 14 Oropharyngeal Neoplasms 14 Lymphoma, Large B-Cell, Diffuse 14 Triple Negative Breast Neoplasms 13 Laryngeal Neoplasms 13 Carcinoma 13 Hypopharyngeal Neoplasms 12 Carcinoma, Hepatocellular 11 Lymphoma 10 Fallopian Tube Neoplasms 10 Carcinoma, Transitional Cell 10 Endometrial Neoplasms 9 Neuroendocrine Tumors 8 Neuroblastoma 8

Interventions

lutetium Lu 177 dotatate 3 pasireotide 2 Octreotide 2 lanreotide 1 copper dotatate CU-64 1 abemaciclib 1 Sunitinib 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Lutetium-177 1 Lutetium 1 Everolimus 1 E-7386 1 Cryotherapy 1 Acupuncture Therapy 1 Acupressure 1 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡